Related Experiment Video
Updated: Aug 5, 2026
11:01
Preparation and In Vivo Use of an Activity-based Probe for N-acylethanolamine Acid Amidase
Published on: November 23, 2016
9.7K
Identification of Azalamellarin N as a Pyroptosis Inhibitor
Jun Takouda1, Moeka Nakamura1, Akane Murasaki1
1Department of Cell Regulation, Graduate School of Biomedical Sciences, Nagasaki University.
Biological & Pharmaceutical Bulletin
|January 3, 2024
Summary
Azalamellarin N (AZL-N) inhibits pyroptosis, a cell death promoting inflammation. This compound targets molecules upstream of NLRP3 inflammasome activation, offering new insights into inflammatory disease mechanisms.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Pyroptosis is a critical inflammatory cell death pathway implicated in various diseases.
- Dysregulation of pyroptosis contributes to the pathogenesis of inflammatory conditions.
- Understanding pyroptosis regulation is crucial for developing targeted therapies.
Purpose of the Study:
- To identify novel chemical inhibitors of pyroptosis.
- To elucidate the mechanism of action of azalamellarin N (AZL-N) in pyroptosis.
- To investigate the upstream targets of AZL-N in pyroptosis regulation.
Main Methods:
- Screening of a compound library to identify pyroptosis inhibitors.
- Induction of pyroptosis using various agonists (R837, extracellular ATP, nigericin).
- Assessing the inhibitory effects of AZL-N on pyroptosis and inflammasome components (caspase-1, ASC).
- Structure-activity relationship analysis of AZL-N.
Main Results:
- Azalamellarin N (AZL-N) was identified as a pyroptosis inhibitor.
- AZL-N showed differential inhibition depending on the NLRP3 inflammasome agonist used.
- AZL-N inhibited caspase-1 and ASC activation, key inflammasome components.
- A lactam ring in AZL-N is essential for its pyroptosis inhibitory activity.
Conclusions:
- AZL-N inhibits pyroptosis, likely by targeting upstream molecules such as protein kinases.
- AZL-N does not directly target NLRP3 inflammasome components.
- Further studies on AZL-N targets will illuminate pyroptosis regulation in inflammatory diseases.
Related Concept Videos
01:18Adrenergic Agonists: Therapeutic Classification
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...